Last reviewed · How we verify
Refractory generalized myasthenia gravis
Approved treatments
- H5G1.1 · AstraZeneca
Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation. - Soliris · Apellis Pharmaceuticals, Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Refractory generalized myasthenia gravis patent landscape — cliff calendar, originator estates, attackable patents
- Refractory generalized myasthenia gravis treatment landscape brief
- Refractory generalized myasthenia gravis treatment updates RSS
Frequently asked questions about Refractory generalized myasthenia gravis
What drugs treat Refractory generalized myasthenia gravis?
Tracked treatments include H5G1.1, Soliris.
What is the treatment for Refractory generalized myasthenia gravis?
Standard treatment for Refractory generalized myasthenia gravis includes H5G1.1, Soliris. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Refractory generalized myasthenia gravis patent cliff · Refractory generalized myasthenia gravis CI report
- Treatment: H5G1.1 · AstraZeneca
- Treatment: Soliris · Apellis Pharmaceuticals, Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing